Plenty of other potential applications for germline editing blur the line between therapy and enhancement. Editing CCR5 with CRISPR could confer lifelong resistance to HIV; editing the APOE gene could lower an individual’s risk of developing Alzheimer’s disease; altered DNA sequences in IFIH1 and SLC30A8 could lower a person’s risk of developing type 1 and type 2 diabetes; and changes to the GHR gene could reduce an individual’s risk of cancer.
